Related Experiment Video
Updated: Nov 14, 2025
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
No difference in HIV-1 integrase inhibitor resistance between CSF and blood compartments
Basma Abdi1, Mouna Chebbi1, Marc Wirden1
1Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, Laboratoire de Virologie, F75013, Paris, France.
Insights
HIV-1 integrase inhibitor resistance in the central nervous system (CNS) is poorly understood. This study found similar resistance profiles in cerebrospinal fluid (CSF) and plasma, suggesting CSF can serve as a marker for CNS resistance.
Area of Science:
- Virology
- Infectious Diseases
- Pharmacology
Background:
- Limited knowledge exists regarding human immunodeficiency virus type 1 (HIV-1) integrase inhibitor resistance within the central nervous system (CNS).
- Understanding resistance patterns in the CNS is crucial for effective HIV-1 treatment strategies.
Purpose of the Study:
- To assess integrase inhibitor resistance in cerebrospinal fluid (CSF) as a surrogate marker for CNS resistance.
- To compare HIV-1 integrase inhibitor resistance in CSF with that observed in plasma.
Main Methods:
- Sequencing of HIV-1 integrase from both plasma and CSF samples of 59 HIV-1 patients.
- Collection of clinical and biological data from routine patient care.
- Analysis of resistance mutations in relation to antiretroviral (ARV) treatment status and HIV-1 subtypes.
Main Results:
- HIV-1 integrase sequences from CSF showed resistance mutations in 33.3% of ARV-naive and 25.0% of ARV-treated patients.
- Common resistance mutations included L74I, T97A, and E157Q.
- Integrase inhibitor resistance patterns in CSF were largely consistent with those found in plasma, with one exception.
Conclusions:
- The study demonstrates comparable integrase inhibitor resistance profiles between the CNS (as indicated by CSF) and plasma in HIV-1 viraemic patients.
- Cerebrospinal fluid can be utilized as a reliable indicator of integrase inhibitor resistance within the CNS.
Background:
Little is known about HIV-1 integrase inhibitor resistance in the CNS.
Objectives:
This study aimed to evaluate integrase inhibitor resistance in CSF, as a marker of the CNS, and compare it with the resistance in plasma.
Methods:
HIV integrase was sequenced both in plasma and CSF for 59 HIV-1 patients. The clinical and biological data were collected from clinical routine care.
Results:
Among the 59 HIV-1 patients, 32 (54.2%) were under antiretroviral (ARV) treatment. The median (IQR) HIV-1 RNA in the plasma of viraemic patients was 5.32 (3.85-5.80) and 3.59 (2.16-4.50) log10 copies/mL versus 4.79 (3.56-5.25) and 3.80 (2.68-4.33) log10 copies/mL in the CSF of ARV-naive and ARV-treated patients, respectively. The patients were mainly infected with non-B subtypes (72.2%) with the most prevalent recombinant form being CRF02_AG (42.4%). The HIV-1 integrase sequences from CSF presented resistance mutations for 9/27 (33.3%) and 8/32 (25.0%) for ARV-naive (L74I, n = 3; L74I/M, n = 1; T97A, n = 1; E157Q, n = 4) and ARV-treated (L74I, n = 6; L74M, n = 1; T97A, n = 1; N155H, n = 1) patients, respectively. Integrase inhibitor resistance mutations in CSF were similar to those in plasma, except for 1/59 patients.
Conclusions:
This work shows similar integrase inhibitor resistance profiles in the CNS and plasma in a population of HIV-1 viraemic patients.
